ArticlePharmaceuticals (Basel, Switzerland)2026
Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database.
Giuseppe Cicala et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.